HIV-1 integrase: structural organization, conformational changes, and catalysis
- PMID: 10384242
- DOI: 10.1016/s0065-3527(08)60306-1
HIV-1 integrase: structural organization, conformational changes, and catalysis
Abstract
Integrase comprises three domains capable of folding independently and whose three-dimensional structures are known. However, the manner in which the N-terminal, catalytic core, and C-terminal domains interact in the holoenzyme remains obscure. Catalytically active recombinant IN can exist in a dynamic equilibrium of monomers, dimers, tetramers, and higher order species. Numerous studies indicate that the enzyme functions as a multimer, minimally a dimer. The IN proteins from HIV-1 and ASV have been studied most carefully with respect to the structural basis of catalysis. Although the active site of ASV IN does not undergo significant conformational changes on binding the required metal cofactor, that of HIV-1 IN does. The reversible, metal-induced conformational change in HIV-1 IN impairs the binding of some anti-HIV-1 IN monoclonal antibodies to the enzyme and results in differential susceptibility of the protein to proteolysis. This active site-mediated conformational change reorganizes the catalytic core and C-terminal domains and appears to promote an interaction that is favorable for catalysis. Other metal-dependent structural changes in HIV-1 IN include the promotion of interactions between the N terminal and the catalytic core domains and the induction of tetramers by zinc ions. The end result of these metal-induced changes is apparently the induction of an activated holoenzyme that can form a stable ternary integrase-metal-DNA complex. These structural changes, which appear to be crucial for optimum catalysis in HIV-1 IN, do not occur in ASV IN. The structural changes observed in HIV-1 IN may serve to recruit the catalytic machinery in this enzyme to a conformation that is native for ASV IN.
Similar articles
-
The conformational feasibility for the formation of reaching dimer in ASV and HIV integrase: a molecular dynamics study.J Biomol Struct Dyn. 2017 Dec;35(16):3469-3485. doi: 10.1080/07391102.2016.1257955. Epub 2016 Nov 28. J Biomol Struct Dyn. 2017. PMID: 27835934 Free PMC article.
-
Structural determinants of metal-induced conformational changes in HIV-1 integrase.J Biol Chem. 1998 Dec 25;273(52):35078-87. doi: 10.1074/jbc.273.52.35078. J Biol Chem. 1998. PMID: 9857042
-
A metal-induced conformational change and activation of HIV-1 integrase.J Biol Chem. 1997 Jun 27;272(26):16196-205. doi: 10.1074/jbc.272.26.16196. J Biol Chem. 1997. PMID: 9195919
-
Crystal structures of catalytic core domains of retroviral integrases and role of divalent cations in enzymatic activity.Adv Virus Res. 1999;52:335-50. doi: 10.1016/s0065-3527(08)60305-x. Adv Virus Res. 1999. PMID: 10384241 Review.
-
Structure and function of HIV-1 integrase.Curr Top Med Chem. 2004;4(9):965-77. doi: 10.2174/1568026043388547. Curr Top Med Chem. 2004. PMID: 15134551 Review.
Cited by
-
Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes.Antimicrob Agents Chemother. 2011 Oct;55(10):4552-9. doi: 10.1128/AAC.00157-11. Epub 2011 Aug 1. Antimicrob Agents Chemother. 2011. PMID: 21807982 Free PMC article.
-
Methods for integration site distribution analyses in animal cell genomes.Methods. 2009 Apr;47(4):261-8. doi: 10.1016/j.ymeth.2008.10.028. Epub 2008 Nov 25. Methods. 2009. PMID: 19038346 Free PMC article.
-
LAP2alpha and BAF collaborate to organize the Moloney murine leukemia virus preintegration complex.EMBO J. 2004 Nov 24;23(23):4670-8. doi: 10.1038/sj.emboj.7600452. Epub 2004 Oct 28. EMBO J. 2004. PMID: 15510219 Free PMC article.
-
Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.Antimicrob Agents Chemother. 2008 Dec;52(12):4228-32. doi: 10.1128/AAC.00487-08. Epub 2008 Oct 6. Antimicrob Agents Chemother. 2008. PMID: 18838586 Free PMC article. Clinical Trial.
-
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.Antimicrob Agents Chemother. 2009 Jul;53(7):2852-6. doi: 10.1128/AAC.01468-08. Epub 2009 May 11. Antimicrob Agents Chemother. 2009. PMID: 19433563 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources